BDTX - NASDAQ
Black Diamond Therapeutics, Inc.
$2.10
-7.1%Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
At a Glance
Live SnapshotBlack Diamond Therapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Moderate working capital outflow. Typical for growing businesses, but ensure it's supporting revenue growth, not inefficiency.
Cash Flow Quality Insight
Exceptional cash generation: High-quality earnings converting to growing free cash flow. The company demonstrates strong pricing power, efficient operations, and disciplined capital allocation.
Black Diamond Therapeutics, Inc. Cash Flow Statement
BDTX • NASDAQ
| Black Diamond Therapeutics, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||||
22.4M | -69.7M | -82.4M | -91.2M | -125.6M | -67.3M | -35.3M | -8.9M | -4.6M | |
325K | 343K | 437K | 508K | 205K | 52K | 47K | 44K | 24K | |
0.0 | 0.0 | 0.0 | 0.0 | 2.2M | 1.7M | 0.0 | 0.0 | 412K | |
6.6M | 10.6M | 9.6M | 12.2M | 14M | 7.8M | 3.6M | 64K | 5K | |
9M | -905K | 2M | 3.3M | 2M | 524K | 6.4M | 15K | 66K | |
-8.7M | -2.7M | 3.7M | -9.9M | 7M | 5M | 463K | 354K | 1.7M | |
29.6M | -62.3M | -66.7M | -85.1M | -100.1M | -52.1M | -24.7M | -8.5M | -2.4M | |
INVESTING ACTIVITIES | |||||||||
(0.0) | (0.0) | -33K | -192K | -2.7M | -142K | -21K | -76K | -77K | |
(27K) | (94K) | (0.0) | (9K) | (2.7M) | (118K) | (0.0) | (0.0) | (0.0) | |
-164M | -122.9M | -61.9M | -60.1M | -49.5M | -372.5M | (0.0) | (0.0) | (0.0) | |
119M | 139.8M | 78.2M | 113.7M | 182.8M | 90.9M | 0.0 | 0.0 | 0.0 | |
74K | 0.0 | 95K | 0.0 | -2.7M | -118K | 0.0 | 0.0 | 0.0 | |
-44.9M | (17M) | (16.3M) | (53.4M) | (130.6M) | -281.7M | -21K | -76K | -77K | |
FINANCING ACTIVITIES | |||||||||
-146K | 24.5M | 71.9M | 177K | 729K | 213.8M | 0.0 | 0.0 | 100K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -50K | |
0.0 | 1.1M | 82K | 0.0 | 0.0 | 1.1M | -1.7M | 0.0 | 10M | |
-146K | 25.5M | 71.9M | 177K | 729K | 214.9M | 127.8M | 52.3M | 10M | |
CASH FLOW SUMMARY | |||||||||
-15.4M | -19.8M | 21.6M | -31.5M | 31.2M | -118.9M | 103.1M | 43.8M | 7.5M | |
37.3M | 57M | 35.5M | 67M | 35.8M | 154.7M | 51.7M | 7.9M | 332K | |
21.8M | 37.3M | 57M | 35.5M | 67M | 35.8M | 154.7M | 51.7M | 7.9M | |
29.6M | -62.3M | -66.8M | -85.3M | -102.9M | -52.3M | -24.7M | -8.5M | -2.4M |
SEC Filings
BDTX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 21, 2026 | May 21, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 29, 2026 | June 26, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 16, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 16, 2026 | March 16, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 03, 2025 | December 03, 2025 | 2025 | |
S-3 S-3 N/A | November 13, 2025 | November 13, 2025 | ||
8-K 8-K 2025 N/A | November 06, 2025 | November 06, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 |
Related Guides
Continue your BDTX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.